Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pumping iron to fight cancer's hidden immune toll

NCT ID NCT07724080

Disease control Sponsor: University of Bath Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

Hormone therapy for prostate cancer often causes muscle loss, which may weaken the immune system by reducing a key signalling protein called IL-7. This trial tests whether a 12-week supervised strength training programme can prevent muscle loss and raise IL-7 levels in men receiving hormone therapy before radiotherapy. Forty men will be randomly assigned to either the exercise programme or usual care, with blood tests and body composition scans before and after the 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a supervised resistance exercise programme (strength training) 3 times per week for 12 weeks
What this could lead to
If it works, this could point toward a simple, drug-free way to protect the immune system during hormone therapy for prostate cancer.
What could go wrong
This is a small pilot study, so results may not be definitive. The exercise programme may not raise IL-7 levels enough to meaningfully affect immunity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed diagnosis of localised prostate cancer (clinical stage T1-3b, N0-1, M0 and a Gleason score of 6-10). * Scheduled to undergo curative-intent treatment involving neoadjuvant androgen deprivation therapy (ADT) for a duration of at least 3 months, alongside radiotherapy. * Recruited prior to, or within the first 2 weeks of, initiating ADT. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Written medical clearance to participate from the treating oncologist. * Sufficient proficiency in English to comprehend study instructions. * Provision of written informed consent. Exclusion Criteria: * Evidence of distant metastases (M1). * Uncontrolled cardiovascular conditions (e.g., uncontrolled hypertension, unstable angina, or a myocardial infarction within the past 6 months). * Musculoskeletal pathologies or conditions that would preclude the safe execution of resistance exercise. * A known history of autoimmune disease. * Current use of chronic systemic corticosteroids or other immunosuppressive agents. * Engagement in structured resistance exercise within the preceding 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Muscle loss are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

muscular atrophy prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Muscle loss Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Bath

    Bath, Somerset, BA2 7AY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.